GLUCAGON-LIKE PEPTIDE-1 IMPROVES BETA-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE

摘要

There is disclosed use of a composition comprising an exendin, or a compound derived therefrom, and a pharmaceutical carrier for the manufacture of a medicament for the treatment of impaired glucose tolerance in individuals who have not been diagnosed with diabetes mellitus, or to reduce the risk of a cardiovascular event or a cerebrovascular event associated with impaired glucose tolerance.